depression
Conditions
Interventions
control:midazolam+dexmedetomidine
treatment:chlorpromazine+dexmedetomidine
Sponsors
The Affiliated Hospital of Shandong Second Medical University
Eligibility
Sex/Gender
All
Age
No minimum to 65 Years
Inclusion criteria
Inclusion criteria: 1.Age5. 4.Patients who do not respond to traditional therapeutic drugs and electroconvulsive. 5.The patients had at least three months with a complaint of depressive mood, anhedonia, somatization, cognitive disturbance, and sleep disorder. 6.Plan to accept therapy with esketamine and dexmedetomidine.
Exclusion criteria
Exclusion criteria: 1.Refuse to participate the study. 2. Contraindication of Dex and esketamine. 3.Preoperative history of schizophrenia, epilepsy, Parkinson’s disease, or myasthenia gravis. 4.Patients with other types of sleep disorders such as sleep apnea, restless legs syndrome, etc. 5.Inability to communicate in the preoperative period because ofcoma, profound dementia, language barrier. 6. Patents with pathological sinus syndrome, severe sinus bradycardia (heart rate<50 beats/min), atrioventricular block of degree II or above, and no implanted pacemaker. 7.Severe hepatic dysfunction (ChildePugh Class C), required preoperative dialysis or expected lifetime < 24 hours. 8.Received treatment with dexmedetomidine or ketamine. 9.Allergy to dexmedetomidine or ketamine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportions of responders and remission (PHQ-9 reduction>50% or PHQ-9<5); | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportions of remission (PHQ-9<5);Score of anxiety, depression and suicide;Score of sleep;Use of anti-psychotic drugs;Readmission;Revisit to psychiatric clinic;Esketamine associated adverse events ; | — |
Countries
China
Contacts
Public ContactJianxiong An
The Affiliated Hospital of Shandong Second Medical University (formerly The Affiliated Hospital of Weifang Medical University)
Outcome results
None listed